A no-dividend policy prioritizing research activities and strengthening the financial position
First written in FY2023. 6 of 7 entries say "Restated". Latest entry: 2026-10-13.
4 other companies' latest entry also says "Restated".
- 2026-10-13RestatedShare Issuance and Disposal
「この方針を変更して銀行借入、社債又は劣後債による資金調達を行うことは、調達額が全額負債となり財務健全性が低下することから、今回の資金調達方法として適当ではないと判断しました。」
借入等ではなく新株予約権による資金調達を選択し、無借金経営の方針を継続している。 - FY2026-H1RestatedAnnual report
「The dividend per share is not presented because no dividend was paid.」
No dividend was paid during the interim accounting period, and the company continued to prioritize allocating resources to research activities and business growth. - 2026-08-05RestatedEarnings
「Fiscal year ending December 2026 (forecast): — 0.00 0.00.」
The forecast for the year-end dividend and annual dividend for the fiscal year ending December 2026 is ¥0.00 in both cases, and the company remains without a dividend. - FY2025RestatedAnnual report
「Regarding our near-term shareholder return policy, we will refrain from paying cash dividends based on the view that we should reward shareholders by allocating management resources to businesses that enhance future shareholder value, implementing those businesses systematically and achieving growth, thereby increasing shareholder value.」
The company continues to prioritize allocating management resources to businesses that enhance future shareholder value rather than paying cash dividends. - FY2025-H1RestatedAnnual report
「The dividend per share is not presented because no dividend was paid.」
No dividend was paid during the interim accounting period, and the no-dividend status continued. - FY2024-H1RestatedAnnual report
「The dividend per share is not presented because no dividend was paid.」
No dividend was paid during the interim accounting period, and the no-dividend status continued. - FY2023First statedAnnual report
「However, since we believe it is important to build retained earnings to secure the research and development expenses necessary for joint drug-discovery research with pharmaceutical companies that will strengthen our financial position and expand our business, we have continued not to pay dividends since our establishment.」
For the time being, the company prioritizes securing research and development expenses and building retained earnings and will continue not to pay dividends. It will consider future shareholder returns in light of operating results and financial condition.